Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Statement: Visit of the Portfolio Committee on Education to the UFS
2005-02-25

The chair of the Portfolio Committee on Education (PCE) Prof Shepherd Mayatula has commended the management of the University of the Free State (UFS) for its positive approach to the incorporation of the Vista and Qwaqwa campuses.

According to a statement issued by the university’s communication section, Prof Mayatula said that while there were outstanding issues to address, a platform had been created through the visit of the portfolio committee for the UFS to find solutions.

Speaking at the end of a visit to the Bloemfontein campus of the UFS, Prof Mayatula said: “You know the issues that exist between the three campuses and you know the solutions. You don’t need recommendations from the Committee.”

Earlier today the PCE held a three-way meeting between the PCE, the management of the UFS and the Vista Task Team, representing staff and students at the Bloemfontein campus of the former Vista University .
 

The Bloemfontein campus of the former Vista University was incorporated into the UFS in January 2004.

The multi-party delegation from the PCE was led by its chairperson, Prof S Mayatula, while the delegation from the UFS was led by the Rector and Vice-Chancellor, Prof Frederick Fourie, while the Vista Task Team was lead by Mr Paseka Mokoena.

Following a presentation by the Vista Task Team and a presentation by the UFS management, other committee members also commended the UFS for the spirit in which outstanding issues were being handled.

It was indicated by portfolio committee members that other universities have far more serious problems than the UFS, and that some of these universities have also been visited by the PCE. The UFS appears to be on the road to be an important pilot case for incorporations and mergers.

The issues that were discussed during today’s meeting included the following:

  • outstanding issues in the process of incorporating the Bloemfontein campus of the former Vista University into the UFS, including:
  • staff issues and conditions of service
  • issues of student aid and pipeline students
  • governance of the UFS
  • the long term utilisation of Vista as a site

The Rector and Vice-chancellor of the UFS, Prof Fourie, expressed his appreciation for the role played by the Portfolio Committee on Education in bringing about a common understanding of the transformation issues facing the UFS.

Prof Fourie said the Portfolio Committee’s visit was a useful intervention to bring about a sense of urgency in resolving matters affecting the Vista campus as well as the Qwaqwa campus.

Issued by: Mr Anton Fisher
Director: Strategic Communication
Cell: 072-207-8334
Tel: 051-401-2749
25 February 2005

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept